ISOThrive Inc.

First of its kind treatment for GERD, novel Mechanism of Action, completed proof of concept data, high return exit potential within 18-24 months

  • Stage Product In Market
  • Industry Biotechnology
  • Location Healdsburg, CA, USA
  • Currency USD
  • Founded November 2013
  • Employees 11
  • Incorporation Type C-corp
  • Website pharma.isothrive.com

Company Summary

ISOThrive originally launched an OTC product in 2016. This enabled the discovery of the product’s efficacy for treating GERD. Reorganized in 2021 to focus on higher value pharmaceutical, the company achieved FDA IND direct to Phase2 approval and launched confirmatory Phase2 study in 2023. Study is on target to be completed by end of Q1 2025. With expected confirmatory data, liquidity event anticipated within 12 months of study completion.

Team

  • Co-Founder, CEO and CTO

    Expert in developing platforms, new products/technologies and launching companies. Specialist in strategy development and execution. Prior successful exit: former company sold to Cavalier Communications Aug 2007 (and later to Motorola). Jack is one of the inventors of ISOThrive and has rapidly become a leading technologist in the microbiome category.

  • Co-Founder and Co-Chief Medical Officer

    Board Certified Family Physician focused on patient health, wellness and prevention. Dartmouth College, Tufts University School of Medicine, Fellow of the American Academy of Family Physicians and the American College of Occupational and Environmental Medicine. Clinical Research Training through NIH. Subject matter expert in the microbiome. Member of Board of Trustees, University of California, Merced.

  • Lee Madsen, II, PhD
    VP and Chief Science Officer

    One of the inventors of ISOThrive and head of the company’s R&D lab. Oversees commercial scale-up, applied R&D and fundamental new research in prebiotics and the microbiome. B.S. Chemistry and Nuclear Science, Ph.D. Analytical and Macromolecular Chemistry from LSU. Specialist in bench-to-pilot process scale-up, expert R&D and regulatory scientist, focus on carbohydrate research and development.

  • Tina Higginbotham
    CP Clinical Research

    Tina has 20+ years’ experience in GI Clinical Research Management, most recently at Vanderbilt University, including over 200 industry-sponsored and investigator-initiated clinical studies. She has extensive experience in regulatory aspects of clinical research, spanning from start-up to close-out. She is experienced in the design and execution of multi-center clinical trials.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free